Advertisement

Advertisement

Breast Cancer
Genomics/Genetics

Should Restrictions on Genetic Testing Be Loosened?

The loosening of restrictions on genetic testing would mean that all health-care providers could help move this needle to where it should be, according to Kevin S. Hughes, MD, a surgeon at Massachusetts General Hospital, Professor of Surgery at Harvard Medical School, and Medical Director of the...

Breast Cancer
Immunotherapy

Immunotherapy ‘Comes of Age’ in Breast Cancer

Immunotherapeutics in breast cancer will likely not be limited to late-stage triple-negative breast cancer. Earlier lines, combination regimens, and expansion into different disease subtypes should become part of this emerging landscape, according to Hope S. Rugo, MD, FASCO, Professor of Medicine...

Breast Cancer

Indigenous American Ancestry May Be Associated With HER2-Positive Breast Cancer

An increased proportion of indigenous American ancestry was associated with a greater incidence of HER2-positive breast cancer, according to a study published in Cancer Research.1 “The risk of breast cancer–related mortality varies between different populations, with Latina women having a greater...

Breast Cancer
Bladder Cancer
Lymphoma
Immunotherapy

FDA Pipeline: Approval of New Dosing for Biosimilar, Plus Two Fast Track Designations

The U.S. Food and Drug Administration (FDA) recently approved a new dose for a biosimilar referencing trastuzumab and granted Fast Track designations to agents for patients with urothelial cancer and follicular lymphoma. Approval of Multidose Vial of Trastuzumab Biosimilar The FDA approved a...

Breast Cancer

Quality of Life After Adjuvant Radiotherapy With vs Without Tumor Bed Boost for Patients With Non–Low-Risk DCIS

In a health-related quality-of-life study reported in The Lancet Oncology, King et al found that adjuvant radiotherapy with a tumor bed boost was associated with poorer cosmetic status and arm and shoulder functional status than radiotherapy with no boost among women with non–low-risk ductal...

Breast Cancer
Immunotherapy

End-of-Study Results From CLEOPATRA: Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

As reported in The Lancet Oncology by Sandra M. Swain, MD, and colleagues, long-term follow-up of the phase III CLEOPATRA trial has shown maintained overall survival benefit with the addition of pertuzumab to trastuzumab plus docetaxel in patients with previously untreated HER2-positive metastatic...

Breast Cancer
Issues in Oncology

Don’t Expect Transgender Patients to ‘Out’ Themselves

Although more transgender patients are presenting to breast centers for imaging, many “report significant social stigma when seeking care,” according to a study in the Journal of Breast Imaging.1 Reported verbal abuse and other forms of harassment “can lead to transgender patients concealing their...

Breast Cancer
Issues in Oncology

Addressing the Needs of Transgender Patients for Breast Cancer Screening in Comfortable and Inclusive Environments

An analysis of breast imaging center websites and a literature search for research articles on transgender breast health found that “issues related to transgender breast imaging are not well addressed in the radiology literature or in the radiology community, even though more transgender patients...

Breast Cancer

I Wasn’t Prepared for the Emotional Turmoil of Breast Cancer

Nearly a decade ago, my mother tested positive for the BRCA1 mutation; soon after, my twin sister and I were tested for the inherited defective gene, and I learned I, too, have the BRCA1 mutation. My sister is not a carrier of the mutation. Although there is a long history of both breast and...

Breast Cancer

Neratinib Combined With Capecitabine in Previously Treated Advanced HER2-Positive Breast Cancer

On February 25, 2020, neratinib (Nerlynx) was approved for use in combination with capecitabine for treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti–HER2-based regimens in the metastatic setting.1,2 Supporting Efficacy ...

Issues in Oncology
Prostate Cancer
Lung Cancer
Breast Cancer
Colorectal Cancer

Patients With Certain Cancers May Be at a Higher Risk for Atrial Fibrillation

People with a history of cancer have an over twofold risk of developing atrial fibrillation, the most common heart rhythm disorder, compared to the general population, according to research presented at the American College of Cardiology’s Annual Scientific Session (Abstract 1216-235). In...

Breast Cancer
Genomics/Genetics

Association of Germline Variant Status and Response to Neoadjuvant Chemotherapy in High-Risk Early Breast Cancer

In a study of the GeparOcto trial population reported in JAMA Oncology, Pohl-Rescigno et al found that presence of germline BRCA1/2 variants was associated with increased rates of complete pathologic response (pCR) to neoadjuvant chemotherapy in women with high-risk early breast cancer, and that a...

Breast Cancer

Digital Breast Tomosynthesis vs Digital Mammography Outcomes: Comparison Over 5 Years

A new study published by Conant et al in the journal Radiology found that the advantages of digital breast tomosynthesis over digital mammography, including increased cancer detection and fewer false-positive findings, are maintained over multiple years and rounds of screening. In addition,...

Breast Cancer

Neoadjuvant Cisplatin vs Doxorubicin/Cyclophosphamide for Patients With HER2-Negative Breast Cancer and a BRCA Mutation

In a phase II trial (INFORM; Translational Breast Cancer Research Consortium [TBCRC] 031) reported in the Journal of Clinical Oncology, Nadine Tung, MD, and colleagues found that neoadjuvant cisplatin did not improve pathologic complete response rate or residual cancer burden vs...

Breast Cancer

New ASCO Guideline Highlights the Management of Male Breast Cancer

THE ANNUAL INCIDENCE of male breast cancer in the United States is dwarfed by the rate among women. Yet, for the estimated 2,670 men who will be diagnosed with breast cancer this year, life-extending and life-enhancing treatments are crucial.1 To help reduce knowledge gaps and improve mortality and ...

Lung Cancer
Gynecologic Cancers
Neuroendocrine Tumors
Breast Cancer

FDA Pipeline: Breakthrough Therapy for NSCLC With Specific Mutation, Approval of Test for Cervical Cancer, and More

Over the past week, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to a bispecific antibody for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations; granted approval to a test for human...

Breast Cancer
Genomics/Genetics

Evaluation of Genetic Testing in NCCN Criteria for Women With Breast Cancer

In a single-institution study reported in the Journal of Clinical Oncology, Yadav et al found that many women with breast cancer with germline pathogenic genetic variants do not qualify for genetic testing on current National Comprehensive Cancer Network® (NCCN®) hereditary testing criteria....

Breast Cancer

Preoperative Letrozole for Postmenopausal Patients With Estrogen Receptor–Positive DCIS

In the phase II CALGB 40903/Alliance trial reported in the Journal of Clinical Oncology, E. Shelley Hwang MD, MPH, and colleagues found that preoperative letrozole was associated with beneficial imaging and biomarker changes in postmenopausal women with estrogen receptor­ (ER)-positive ductal...

Breast Cancer

Receipt of Adjuvant vs Neoadjuvant Chemotherapy and Start of Treatment in Patients With Breast Cancer

Research published by Melchior et al in Cancer Medicine has indicated that starting chemotherapy before surgery does not expedite the start or completion of treatment for breast cancer vs performing surgery first. “Increasingly, patients are given [neoadjuvant] chemotherapy…This is done for breast ...

Breast Cancer

Therapy Is Keeping My Metastatic Breast Cancer Manageable

Despite being vigilant about adhering to my annual schedule of screening mammography, in 2002, I was diagnosed with stage III triple-negative breast cancer. The diagnosis scared me, and I wondered if I was going to die. Determined to do what I could to survive the cancer, I underwent aggressive...

Breast Cancer

Former ASCO President Sandra M. Swain, MD, FACP, FASCO, Shares Highlights of a Noted Career

In this edition of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Sandra M. Swain, MD, FACP, FASCO, Professor of Medicine and Associate Dean for Research Development at Georgetown University Medical Center, and Vice President of MedStar Genetic Medicine at Medstar...

Breast Cancer

21-Gene Assay Recurrence Score and Risk of Locoregional Recurrence in Hormone Receptor–Positive, Node-Positive Breast Cancer

A retrospective analysis from the Southwest Oncology Group S8814 trial, reported by Wendy A. Woodward, MD, PhD, of the Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, and colleagues in JAMA Oncology,1 showed that a low 21-gene assay recurrence score was...

Breast Cancer

Brief Highlights From the 2019 San Antonio Breast Cancer Symposium

In addition to our regular coverage of the 2019 San Antonio Breast Cancer Symposium, the following reports from the meeting include studies you may have missed. We hope you find them of interest. Ribociclib/Letrozole as Neoadjuvant Therapy As neoadjuvant therapy in women with high-risk hormone...

breast cancer

Hongchao Pan, PhD, on an Update on 5 Years of Endocrine Therapy for Early Breast Cancer

Hongchao Pan, PhD, of the University of Oxford, discusses an analysis of 86,000 women in the Early Breast Cancer Trialists’ Collaborative Group database, which showed that the risk of distant recurrence 20 years after a diagnosis of node-negative, estrogen receptor–negative early-stage breast cancer in women who discontinued endocrine therapy at 5 years is likely to be about a third lower now than in his group’s previous report (Abstract GS2-04).

Breast Cancer

ASCO and CAP Release Updated Guideline on Estrogen and Progesterone Testing in Breast Cancer

ASCO and the College of American Pathologists (CAP) have jointly published an update to a clinical practice guideline on estrogen receptor and progesterone receptor testing in breast cancer.1 The guideline for immunohistochemistry testing of estrogen receptor and progesterone receptors in patients...

Breast Cancer
Issues in Oncology
Cost of Care

Young Women Diagnosed With Breast Cancer May Face Employment Disruption and Financial Hardship

A study evaluating the economic impact of the cancer in young women has found that the diagnosis can result in employment disruption and financial decline. The findings—published by Tangka et al in Cancer Epidemiology, Biomarkers & Prevention—indicate the need for obtaining and maintaining...

Breast Cancer

NSABP B-42 Trial 10-Year Update: Impact of Extended Letrozole on Disease-Free Survival

“In the 10-year analysis of the NSABP B-42 trial, the effect of extended treatment with 5 years of letrozole on disease-free survival persisted and reached statistical significance. There was no significant improvement in overall survival with letrozole, but letrozole continued to provide a...

Breast Cancer

Investigators in Brazil Explore Availability, Cost, and Use of Biosimilar Trastuzumab in Patients With HER2-Positive Breast Cancer

Investigators in Brazil are seeking to explore the efficacy and safety of adjuvant biosimilar trastuzumab in a real-world study of patients with early HER2-positive breast cancer. In 2019, biosimilar trastuzumab became the first biosimilar approved in Brazil for the treatment of patients with...

Immunotherapy
Breast Cancer

Small Study Explores Impact of Novel Regimen on Pembrolizumab for Triple-Negative Breast Cancer

In the phase II KEYNOTE-890 trial, patients with inoperable advanced triple-negative breast cancer who received one intratumoral tavokinogene telseplasmid injection followed by electroporation and pembrolizumab, several patients with skin or subcutaneous tumors saw metastatic lesions disappear,...

Breast Cancer
Immunotherapy

Phase III SOPHIA Trial Evaluates Margetuximab/Chemotherapy vs Trastuzumab/Chemotherapy for HER2-Positive Breast Cancer

The second interim analysis of the phase III SOPHIA trial demonstrated a significant though modest improvement in progression-free survival, response rate, and clinical benefit with the addition of margetuximab to chemotherapy vs trastuzumab plus chemotherapy in patients with HER2-positive...

Immunotherapy
Breast Cancer

Phase III KEYNOTE-522: Pembrolizumab Benefits Outcome in Neoadjuvant, Adjuvant Settings in Triple-Negative Breast Cancer

In patients with triple-negative breast cancer, the addition of pembrolizumab to neoadjuvant and adjuvant chemotherapy achieves higher rates of pathologic complete response compared with placebo, according to results of the phase III KEYNOTE-522 trial presented at the 2019 San Antonio Breast Cancer ...

Breast Cancer

Adding Capecitabine to Systemic Therapies Improves Outcomes in Triple-Negative Breast Cancer

Capecitabine improves disease-free and overall survival for patients with triple-negative breast cancer, but only when it is added to other systemic therapies, not when it is used as a substitute, according to a large meta-analysis of the effects of capecitabine in early breast cancer, The results...

Breast Cancer

Expert Point of View: A. Jo Chien, MD

A. Jo Chien, MD, Associate Professor at UCSF’s Helen Diller Comprehensive Cancer Center, San Francisco, was the formal discussant of this abstract. Dr. Chien said that a median follow-up of 3-years is relatively short for this trial, considering about 75% of patients had hormone receptor–positive...

Breast Cancer

Adjuvant Ado-Trastuzumab Emtansine vs Paclitaxel Plus Trastuzumab in Early HER2-Positive Breast Cancer

Results of the randomized, phase II ATEMPT trial showed that the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) failed to demonstrate improved safety when compared with paclitaxel plus trastuzumab as adjuvant therapy in patients with stage 1 HER2-positive breast cancer. These results of...

Breast Cancer

Expert Point of View: Steven J. Isakoff, MD, PhD

Steven J. Isakoff, MD, PhD, a medical oncologist at Massachusetts General Hospital, Boston, commented on the results of the DESTINY-Breast01 trial. “These data are extraordinarily encouraging, suggesting we will have another new option for patients with metastatic HER2-positive breast cancer. The...

Breast Cancer

Phase II DESTINY-Breast01: T-DXd Effective in Pretreated, Metastatic HER2-Positive Breast Cancer

In heavily pretreated patients with HER2-positive metastatic breast cancer [fam-]trastuzumab deruxtecan-nxki (T-DXd), a novel antibody-drug conjugate, achieved high response rates and durable responses, according to results of the phase II DESTINY-Breast01 trial presented at the 2019 San Antonio...

Breast Cancer

Expert Point of View: Steven J. Isakoff, MD, PhD

“With longer follow-up, the addition of pertuzumab to chemotherapy and trastuzumab appears to show benefit in hormone receptor–­positive patients as well. In practice, we offer this regimen to node-positive patients and we are encouraged that hormone receptor-positive and -negative patients have a...

Breast Cancer

Chemotherapy, Trastuzumab, and Pertuzumab in Early HER2-Positive, Node-Positive Breast Cancer: Six-Year Follow-up of APHINITY Trial

Martine J. Piccart, MD, PhD, FASCO, reported that at 6-year follow-up of the APHINITY trial there was a modest, but not statistically significant, overall survival benefit for the addition of pertuzumab to chemotherapy plus trastuzumab vs chemotherapy/trastuzumab as adjuvant therapy in patients...

Breast Cancer

Phase III HER2CLIMB Trial Yields Positive Data in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis

The investigational oral agent tucatinib added to trastuzumab/capecitabine reduced the risk of death by one-third and reduced the risk of disease progression or death by one-half in patients with heavily pretreated metastatic HER2-positive breast cancer, including those with untreated or previously ...

Breast Cancer
Immunotherapy

Conference Highlights From the 2019 San Antonio Breast Cancer Symposium

More than 7,500 specialists in breast oncology from over 90 countries attended the 2019 San Antonio Breast Cancer Symposium (SABCS) held last December. Researchers convened to present a wide-ranging array of abstracts and posters featuring important new data in the treatment of breast cancer....

Breast Cancer

Anthracycline-Based Chemotherapy vs Docetaxel/Capecitabine: What’s the Better Adjuvant Therapy for Early Breast Cancer?

As reported in the Journal of Clinical Oncology by Delaloge et al, a second randomized component of the phase III EORTC 10041/BIG 3-04 MINDACT trial, though underpowered, suggested no benefit of docetaxel/capecitabine vs standard anthracycline-based adjuvant therapy for patients with early breast...

Breast Cancer

AI Algorithms Plus Radiologist Assessment May Help Improve Accuracy in Reading Mammography Results

An ensemble of machine-learning algorithms could help improve the accuracy of breast cancer screenings when used in combination with assessments from radiologists, according to a study published by Schaffter et al in JAMA Network Open. The study was based on results from the Digital Mammography...

Breast Cancer
Immunotherapy

Neoadjuvant and Adjuvant Pembrolizumab in Early Triple-Negative Breast Cancer

As reported in The New England Journal of Medicine by Peter Schmid, MD, PhD, and colleagues, interim analyses of the phase III KEYNOTE-522 trial have shown that the addition of pembrolizumab to neoadjuvant chemotherapy and use of adjuvant pembrolizumab vs placebo resulted in improvements in...

Breast Cancer
Issues in Oncology

Weight Gain After Breast Cancer Diagnosis in Australia: Survey Results

New study findings suggest that weight gain after breast cancer is a greater problem than previously thought. The first national survey on weight after breast cancer in Australia, published by Ee et al in BMC Cancer, found close to two-thirds (63.7%) of women reported weight gain at an average of...

Lung Cancer
Head and Neck Cancer
Gynecologic Cancers
Breast Cancer

FDA Pipeline: Priority Review in Lung Cancer, Breakthrough Therapy Designation in Head and Neck Cancer, and More

This week, the U.S. Food and Drug Administration (FDA) granted Priority Review to brigatinib for the treatment of ALK-positive lung cancer and Breakthrough Therapy designation to a potential first-in-class oral antagonist of inhibitors of apoptosis proteins for the treatment of head and neck...

Breast Cancer

Abbreviated Breast MRI vs Digital Breast Tomosynthesis Screening in Women With Dense Breasts

As reported in JAMA by Christiane K. Kuhl, MD, PhD, and colleagues, the ECOG-ACRIN EA1141 trial has shown that abbreviated breast magnetic resonance imaging (MRI) was associated with a significantly higher invasive breast cancer detection rate vs digital breast tomosynthesis among women with dense...

Breast Cancer
Issues in Oncology

Are There Differences in Treatment and Outcomes for African American and White Women With Triple-Negative Breast Cancer?

In a study using Henry Ford Health System data reported in a research letter in JAMA Surgery, Chen et al found little difference in treatment and outcomes between African American and white women with nonmetastatic triple-negative breast cancer. Screen detection of disease was associated with...

Breast Cancer

FDA Approves Neratinib/Capecitabine for Pretreated Patients With Metastatic HER2-Positive Breast Cancer

On February 25, the U.S. Food and Drug Administration (FDA) approved neratinib (Nerlynx), a tyrosine kinase inhibitor, in combination with capecitabine for adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2–based regimens in the...

Breast Cancer
Immunotherapy

Trastuzumab Deruxtecan in HER2–Low-Expressing, Previously Treated Advanced Breast Cancer

In a phase Ib study reported in the Journal of Clinical Oncology, Shanu Modi, MD, and colleagues found that the antibody-drug conjugate trastuzumab deruxtecan was active in HER2–low-expressing, previously treated advanced breast cancer. The drug component is a topoisomerase I inhibitor. The agent...

Breast Cancer
Immunotherapy

Expert Point of View: Kevin Kalinsky, MD, MS

Commenting on SAFIR02-IMMUNO for The ASCO Post, Kevin Kalinsky, MD, MS, Associate Professor of Medicine at ­NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, said the findings of the analysis were in accordance with other studies in metastatic breast cancer, but they came...

Advertisement

Advertisement

Advertisement